Antibacterial agents and potentiators of carbapenem antibiotics

ABSTRACT

New 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids are described which display antibacterial activity and potentiate carbapenem antibiotics.

This is a continuation of application Ser. No. 356,642, filed May 22,1989, now abandoned, which is a continuation of application Ser. No.927,027, filed Nov. 5, 1986, now abandoned.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to new antibacterial agents which interfere inbacterial cell wall synthesis by inhibiting the enzyme D-Ala-D-Alaligase. Compounds of this invention also inhibit renal dehydropeptidase(DHP) and, therefore, potentiate the antibiotic activity of carbapenemantibiotics.

2. Brief Description of the Art

Many antibacterial agents owe their selective toxicity to the fact thattheir targets are structures which are only present in the sensitivebacterium. One of these structures is peptidioglycan a cell wall polymerwhich plays a vital role in protecting bacteria from lysis. A number ofagents, e.g., β-lactams, bacitracin, and flavomycin, interfere with theassembly of this polymer by inhibiting enzymatic reactions involved inthe final stages of assembly.

Peptidoglycan biosynthesis involves a precursor,UDP-MurNac-Ala-D-Glu-Lys-D-Ala-D-Alanine that is biosynthesized in amultienzyme pathway which terminates in the addition ofD-Alanine-D-Alanine to the UDP-MurNAc-tripeptide. The formation ofD-Alanyl-D-Alanine is catalyzed by D-Alanyl-D-Alanine ligase(synthetase). It is known that inhibition of D-Alanyl-D-Alanyl ligasewill terminate peptidoglycan biosynthesis resulting in vivo in bacterialcell lysis. Such inhibitors can serve as antibacterials. For example,D-Cycloserine, a D-Alanine mimic, is a reversible inhibitor of theligase at both the donor and acceptor sites and is the most potentligase inhibitor described heretofore, and is a potent antibacterial.(F. C. Neuhaus et al., Biochemistry 3, 471-480 (1964)).

Dipeptide analogs of D-Alanyl-D-Alanine are also known to be inhibitorsof ligase. (F. C. Neuhaus et al., Biochemistry 8, 5119-5124 (1965), andF. C. Neuhaus and W. P. Hammes, Pharmac. Ther. 14, 265-319 (1981)).

Renal dehydropeptidase (E.C. 3.4.13.11) is a mammalian enzyme whichmetabolizes carbapenem antibiotics such as thienamycin and imipenem.Inhibition of this enzyme enhances the urinary recovery of theseantibiotics and reduces their renal toxicity. EPO Publication No.0091594 to Sanraku-Ocean Co., Ltd. describes aminocarboxylic acidderivatives possessing dipeptidase inhibiting activity. This subject andthe development of cilastatin as a renal dehydropeptidase inhibitor foruse in combination with imipenem have also been reviewed by F. M. Kahanet al., J. Antimicrobial Chemotherapy, 12, Suppl. D, 1-35 (1983).

U.S. Pat. No. 4,374,131 to Petrillo (assigned to E. R. Squibb & Sons,Inc.) discloses amino and substituted amino phosphinyl-alkanoylcompounds which are useful hypertensive agents due to theirangiotensin-converting-enzyme (ACE) inhibition activity.

E. D. Thorsett et al., (Merck & Co., Inc.) Proc. Natl. Acad. Sci. USAVol. 79, pp 2176-2180 (April, 1982) discloses phosphorus containinginhibitors of angiotensin-converting enzyme.

With this background, the search for newer and more effectiveantibacterial agents which are ligase inhibitors, is a continuing one.

SUMMARY OF THE INVENTION

It has been found that compounds of Structures I and II, shown below,are inhibitors of D-Alanyl-D-Alanine ligase, and are useful in thetreatment of bacterial infections. These compounds may be administeredalone or in combination with other antibiotics such as D-cycloserine orβ-lactam antibiotics. These compounds also inhibit renaldehydropeptidase E.C. (3, 4, 13, 11) and are useful to potentiate the invivo effects of penem and carbapenem antibiotics such as imipenem.

By this invention there is provided phosphinodipeptides of formulas Iand II; ##STR1## wherein:

R₁ is H or CH₃ ;

R₂ and R₅ are selected from

(a) hydrogen,

(b) C₁ -C₁₂ linear or branched alkyl;

(c) C₂ -C₁₂ linear or branched monoalkenyl;

(d) C₇ -C₂₀ aralkyl, wherein the alkyl chain is linear or branched C₁-C₈ ;

(e) heterocyclic alkyl, wherein the alkyl chain is linear or branched C₁-C₈ and the heterocyclic ring is 5-6 membered, optionally fused with abenzene ring, fully aromatic, and containing 1-3 O, N or S heteroatoms;

wherein said above groups for R₂ and R₅ can be substituted by one ormore: halo, hydroxy, carboxy, C₁ -C₄ alkoxycarbonyl, C₇ -C₁₆arylalkoxycarbonyl, C₃ -C₇ cycloalkyl, C₁ -C₄ alkoxy, C₆ -C₁₂ aryloxy,amino, mono- or di-C₁ -C₈ alkylamino, thio, C₁ -C₄ alkylthio, C₆ -C₁₂arylthio, C₇ -C₁₆ aralkylthio, or the radical --S--(CH₂)_(n)--CH(NH₂)COOH,

where n=1-2;

with the proviso that R₂ or R₅ is at least C₂ alkyl if substituted byone of the above-defined thio groups, and wherein the aryl or aromaticheterocyclic rings can be further substituted by C₁ -C₄ linear orbranched alkyl, trihalomethyl, nitro, halo, cyano or sulfonamido;

R₃ and R₄ are hydrogen, C₁ -C₄ alkyl, C₆ -C₁₂ aryl or C₇ -C₁₆ aralkyl;

and including stereoisomers and racemates thereof.

Also provided is a pharmaceutical composition useful in the treatment ofantibacterial infections which comprises a pharmaceutically acceptablecarrier and a pharmaceutically effective amount of an antibacterialcompound of formulae I or II, or mixture thereof: ##STR2## wherein:

R₁ is H or CH₃ ;

R₂ and R₅ are as defined above;

R₃ and R₄ are independently selected from hydrogen, lower alkyl, aryllower alkyl;

wherein the carbon atom (linked to phosphorus) attached to R₁ is in theD(S) or DL(SR) stereoconfiguration; to R₂, in the D(R) or DL(RS)stereoconfiguration; and if R₅ is present the double bond is in the E orZ configuration.

Preferred embodiments of Structures I and II for antibacterial activityinclude: R₁ is methyl; R₂ and R₅ are small radicals such as methyl,ethyl, bromomethyl, chloromethyl and the like; and the carbon attachedto R₁ is in the D(S) stereoconfiguration.

Further provided is a pharmaceutical composition useful in the treatmentof antibacterial infections which comprises a pharmaceutically effectiveamount of a DHP-inhibiting compound of Formula I or II, or mixturethereof, in combination with a pharmaceutically effective amount of acarbapenem or penem antibiotic: ##STR3## wherein:

R₁ is H or CH₃ ;

R₂ and R₅ are as defined above;

R₃ and R₄ are independently selected from hydrogen, lower alkyl, aryllower alkyl;

and the carbon (linked to phosphorus) attached to R₁ is in the L(R) orDL(RS) configuration; the carbon attached to R₂ is in the D(R), L(S) orDL(RS) configuration; and if R₅ is present, the double bond is in the Eor Z configuration.

Preferred embodiments of Structure I and II for DHP inhibiting activityare where, R₁ is methyl; R₂ and R₅ are long chain alkyl groups, such asn-heptyl, n-hexyl, which can be substituted with groups such as halo,hydroxy, carboxy, C₁ -C₄ alkoxycarbonyl, C₇ -C₁₆ arylalkoxycarbonyl, C₃-C₇ cycloalkyl, C₁ -C₄ alkoxy, C₆ -C₁₂ aryloxy, amino, mono- or di-C₁-C₈ alkylamino, thio, C₁ -C₄ alkylthio, C₆ -C₁₂ arylthio, C₇ -C₁₆aralkylthio, or the radical --S--(CH₂)_(n) --CH(NH₂)COOH, where n=1-2;with the proviso that R₂ or R₅ is at least C₂ alkyl if substituted byone of the above-defined thio groups, and wherein the aryl or aromaticheterocyclic rings can be further substituted by C₁ -C₄ linear orbranched alkyl, trihalomethyl, nitro, halo, cyano or sulfonamido; thechain carbon (alpha to phosphorus) attached to R₁ is preferably of L (R)stereoconfiguration; and if R₅ is present, it is in the Zstereoconfiguration.

DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

The novel compounds of the above Structural Formulas I and II representnew and useful antibacterial agents and dehydropeptidase inhibitors.

The values of the alkyl and alkenyl groups for R² and R⁵, except wherenoted otherwise, represented by any of the variables include linear orbranched, alkyl and monoalkenyl and chain hydrocarbon radicals from oneto twelve carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl,n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, n-heptyl,n-nonyl, 4,4-dimethylpentyl, or vinyl, allyl, 1-butenyl, 2-butenyl,5-hexenyl and the like. Preferred for antibacterial activity are ethyland chloromethyl. Preferred for DHP inhibition are n-butyl, n-pentyl,n-heptyl or 1-butenyl.

The aralkyl group represented by the above variables has from one toeight carbon atoms in the alkyl portion and "aryl" where noted,represents phenyl, naphthyl, or biphenyl. Representative examplesinclude benzyl, phenethyl, 4-phenyl-n-butyl, δ-phenyl-n-octyl, and thelike.

The aromatic heterocyclic, i.e. "heteroaryl" substituent, aresynonymous, and recited above represents a 5- or 6-membered aromaticring containing from one to three O, N or S heteroatoms, preferably oneO or S and/or 1,3N heteroatoms, such as, for example, pyridyl, thienyl,furyl, imidazolyl, and thiazolyl as well as any bicyclic group derivabletherefrom in which any of the above heterocyclic rings is fused to abenzene ring such as, for example, indolyl, quinolinyl, isoquinolinyl,benzimidazolyl, benzothiazolyl, benzofuryl, and benzothienyl.

The named substituents on the alkyl and alkenyl chains can be present onthe aromatic rings in the aralkyl, heterocyclic alkyl and heteroarylgroupings as well. Site of substitution includes all available sites andsubstitution can involve one or more of the same or different groups.

The substituents are: halo, meaning fluoro, chloro, bromo or iodo;hydroxy; carboxy; C₁ -C₄ linear or branched alkoxycarboxy, e.g.methoxycarbonyl and ethoxycarbonyl; C₇ -C₁₆ arylalkoxy carbonyl, e.g.benzyloxycarbonyl, n-butyloxycarbonyl; C₃ -C₇ cycloalkyl, e.g.cyclopentyl and cyclohexyl; C₁ -C₄ alkoxy, e.g. t-butoxy and ethoxy; C₆-C₁₂ aryloxy, e.g. biphenyloxy, benzyloxy; amino; mono- or di-C₁ -C₈dialkylamino, e.g. methylamino, isopropylamino, n-butylamino,isohexylamino, N,N-diethylamino, methylethylamino, methyl-t-butylamino,di-n-octylamino; thio; C₁ -C₄ alkylthio, e.g. methylthio, ethylthio; C₆-C₁₂ arylthio, e.g. phenylthio; C₇ -C₁₆ aralkylthio, e.g. benzylthio,naphthylmethylthio; the radicals --S--CH₂ --CH(NH₂)COOH and --S--(CH₂)₂--CH(NH₂)COOH, both preferably in the L-configuration; and, where a thiosubstituent is present, R₂ /R₅ must be at least a C₂ alkyl grouping.Where an aryl or heteroaryl group is present in the substituent, thering carbons can additionally be substituted by one or more of linear orbranched C₁ -C₄ alkyl, e.g. methyl, ethyl, isopropyl, t-butyl;trihalomethyl, "halo" having the same meaning as described above, e.g.trichloromethyl, trifluoromethyl; nitro, cyano or sulfonamide.

Preferred are the compounds wherein:

R₁ is methyl;

R₂ and R₅ are:

C₁ -C₁₀ linear or branched alkyl;

C₇ -C₁₄ aralkyl;

wherein both groups can be substituted with halo, amino, mono- or di-C₁-C₄ linear or branched alkylamino, carboxyl, C₁ -C₄ alkoxycarbonyl,hydroxy, C₁ -C₄ alkoxy, C₅ -C₆ cycloalkyl, C₆ -C₁₀ aryloxy, thio, C₁ -C₄linear or branched alkylthio, C₆ -C₁₀ arylthio, C₇ -C₁₄ aralkylthio,--S--(CH₂)_(n) --CH(NH₂)CO₂ H, where n=1-2, with the proviso that R₂ orR₅ is at least C₂ alkyl if substituted by one of the above-defined thiogroups and wherein the aryl group ring carbons can further besubstituted by linear or branched C₁ -C₄ alkyl; R₃ and R₄ are hydrogen,C₁ -C₄ linear or branched alkyl e.g. methyl, ethyl, or C₇ -C₁₄ aralkyle.g. benzyl.

Preferred compounds of Structure I for antibacterial activity includethose in which the stereochemical configurations of the carbon (linkedto phosphorus) attached to R₁ are D(S), DL(SR), and the chain carbonattached to R₂ are, respectively, D(R), DL(RS). Particularly preferredis where the stereochemical configurations of the carbons attached to R₁and R₂ are D(S) and D(R) respectively.

Preferred compounds of Structure II for antibacterial activity includethose in which the stereochemical configuration of the carbon atomattached to R₁ is D and the configuration of the double bond is Z or E.

The preferred compounds of Structures I or II, for use as DHP inhibitingagents include those having the carbon attached to R₁ in the L(R)configuration and the carbon attached to R₂ in the D(R) or L(S)configuration and if R₅ is present, the double bond is preferred in theZ configuration.

The Formulas I and II compounds can be used in the form of salts derivedfrom inorganic or organic acids and bases. Included among such acidaddition salts are the following: acetate, adipate, alginate, aspartate,benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate,ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate,hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide,hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate,pectinate, persulfate, 3-phenylpropionate, picrate, pivalate,propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate.Base salts include ammonium salts, alkali metal salts such as sodium andpotassium salts, alkaline earth metal salts such as calcium andmagnesium salts, salts with organic bases such as dicyclohexylamine andN-methyl-D-glucamine, and salts with amino acids such as arginine,lysine, and so forth. Water or oil-soluble or dispersible products arethereby obtained.

Further embodiments of this invention are the use of the compounds offormulas I and II as antibacterials agents administered separately or incombination with other antibacterials such as D-cycloserine, fosfomycin,pentizidone, cefoxitin, ceftazidine, thienamycin, imipenem, ampicillin,and the like.

The pharmaceutical composition useful in the treatment of antibacterialinfections preferably comprises a pharmaceutically acceptable carrierand a pharmaceutically effective amount of an antibacterial compound offormulae I or II, or mixture thereof: wherein the compound contains thecarbon atoms attached to R₁ and R₂ in the D configuration and if R₅ ispresent, the double bond is in the E or Z configuration.

Specific preferred antibacterial compounds useful in the compositioninclude: 1-(aminoethyl)-(2-carboxy-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carbomethoxy-n-proypl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-butyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-5-phenyl-n-pentyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-nonyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-5-(4-pyridyl)-n-pentyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-3-chloro-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-3-bromo-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-hexyl) phosphinic acid,1-aminoethyl-(2-carboxy-2-n-octenyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-2-propenyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-4-phenyl-2-butenyl) phosphinic acid, and1-(aminoethyl)-(2-carboxy-5-phenyl-2-pentenyl) phosphinic acid.

The pharmaceutical composition can further comprise an effective amountof a second antibacterial compound in combination selected from.D-cycloserine, fosfomycin, pentizidone, cefoxitin, ceftazidine,thienamycin, imipenem, ampicillin, and the like.

Also provided is a method for treating a bacterial infection in amammalian host comprising administering to said host a therapeuticallyeffective amount of the above-described composition.

In pharmaceutical compositions useful in the treatment of antibacterialinfections which comprise a pharmaceutically effective amount of acompound of Formula I or II, or mixture thereof, in combination with apharmaceutically effective amount of a carbapenem or penem antibioticthe carbon attached to R₁ in the L(R) configuration and the carbonattached to R₂ in the D(R) or L(S) configuration and if R₅ is present,the double bond is preferred in the Z configuration.

Specifically preferred DHP-inhibiting compounds useful in thecomposition include: 1-(aminoethyl)-(2-carboxy-n-propyl) phosphinicacid, 1-(aminoethyl)-(2-carbomethoxy-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-butyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-5-phenyl-n-pentyl-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-nonyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-5-(4-pyridyl)-n-pentyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-3-chloro-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-3-bromo-n-propyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-n-hexyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-2-n-octenyl) phosphinic acid,1-(aminoethyl)-(2-carboxy-2-propenyl)-phosphinic acid,1-(aminoethyl)-(2-carboxy-4-phenyl-2-butenylpropyl)-phosphinic acid, and1-(aminoethyl)-(2-carboxy-5-phenyl-2-pentenyl) phosphinic acid.

Also provided is a method for treating a bacterial infection in amammalian host comprising administering to said host a therapeuticallyeffective amount of the above-described composition.

D-Alanyl-D-Alanine Ligase In Vitro Activity

The ligase enzyme inhibitory activity of compounds of Formula I havebeen evaluated in vitro with only minor modifications of the proceduresof F. C. Neuhaus (Biochemistry 3, 471-480 (1964) and references citedtherein) using D-cycloserine as a control and standard ligase inhibitor.The procedure is as follows:

D-ALANYL-D-ALANINE LIGASE METHOD

Streptococcus faecalis (ATCC 8043) was grown as described by Neuhaus (J.Biol. Chem., 237:778, 1962). Cell-free extracts were prepared bysonication followed by centrifugation at 27,000 x g for 30 minutes.Protein was precipitated with 55% ammonium sulfate. The precipitate wasdissolved in 0.05M Tris-Cl buffer (pH 7.0), dialyzed against 0.002Mglutathione and stored in liquid nitrogen. No loss of activity wasobserved after 1 year.

The assay mixture contained 0.05M Tris-Cl buffer (pH 7.9), 0.01M KCl,0.008M MgCl₂, 0.005M ATP, 0.005M (14C-l)-D-alanine and 5 μl of enzyme(specific activity=0.38 units/mg protein). Assay volume was 0.1 ml.

Inhibitors were pre-incubated with enzyme, MgCl₂, KCl and buffer, for 40minutes at room temperature, before addition of ATP and substrate.Samples were subsequently incubated at 37° C. for 30 minutes.

Twenty μl of each sample was applied to the preabsorbent layer of highresolution, prechanneled silica-gel TLC plates to stop the reaction.Plates were developed in ethanol:ammonium hydroxide:H₂ O (11:1:8) for2-3 hours and the radioactive zones located and integrated with aBerthold Linear Analyzer. IC50's were determined for active compounds(70% inhibition) in ethanol:ammonium hydroxide:H₂ O (11:1:8) for 2-3hours and the radioactive zones located and integrated with BertholdLinear Analyzer. IC50's were determined for active compounds (70%inhibition).

Representative test data with compounds of this invention using theabove procedure are shown below.

    ______________________________________                                        DAlaAla Liquase Inhibition                                                    ______________________________________                                         ##STR4##                                                                     Stereochemistry                                                               at the methyl position                                                                      R.sub.2 (DL)                                                                              R.sub.3 IC.sub.50 (μM)                           ______________________________________                                        DL            H           H       535                                         DL            methyl      H       165                                         D             methyl      H       124                                         DL            methyl      methyl  60                                          DL            ethyl       H       50                                          D             ethyl       H       45                                          DL            phenylpropyl                                                                              H       20                                          DL            n-heptyl    H       12.5                                        D             n-heptyl    H       4                                           ______________________________________                                         ##STR5##                                                                     Stereochemistry                                                               at the methyl position                                                                      R.sub.5         IC.sub.50 (μM)                               ______________________________________                                        D             H               210                                             DL            n-pentyl, (E, Z isomers)                                                                      700                                             DL            benzyl (E isomers)                                                                            210                                             ______________________________________                                    

II. In Vitro Antibacterial Assay of Compounds of Formulas I & II

The antibacterial data shown below were obtained using a synthetic agarmedium described by F. R. Atherton et al., Antimicrobial Agents andChemotherapy, 15, 677 (1979).

    __________________________________________________________________________    ANTIBACTERIAL RESULTS                                                         (Minimum Inhibitory Concentrations from Agar Dilution Assays in mg/ml)         ##STR6##                                                                     __________________________________________________________________________    Stereochemistry                                                                          DL   D    DL   D    DL   D    D      D                             of methyl                                                                     R.sub.2 (DL)                                                                             methyl                                                                             methyl                                                                             methyl                                                                             ethyl                                                                              phenyl-                                                                            n-heptyl                                                                           ClCH.sub.2                                                                           --                                                           propyl                                         R.sub.3    H    H    methyl                                                                             H    H    H    H      H                             R.sub.5    --   --   --   --   --   --   --     H                             Staph. aureus-2865                                                                       >256 >256 >256 >256 >256 128  >256   >256                          Strep. faecalis-2864                                                                     --    64  128   16  256   64  128     256                          E. coli TEM 2+                                                                           128  256  256   64  "    128  "      >256                          E. coli DC2                                                                              128  256   64   32  128   32  "      "                             E. coli    >256 >256 >256 128  "    128  >256   "                             Sal. typh. "    "    "    256  "    128  "      "                             Ent. cloacae                                                                             "    "    256  128  >256 256  256    "                             Klebs. pneum.                                                                            "    256  >256 256  256   64  128      64                          Prot. vulg.                                                                              "    "    256  128  >256 128   64    >256                          Pseud. aerug.                                                                            "    128  128   32  "    >256  16     128                          Serratia marcescens                                                                      "    >256 >256 >256 "    "    >256   >256                          __________________________________________________________________________

Compounds of this invention also inhibit dehydropeptidase-I (renaldipeptidase, EC 3.4.13.11) and, therefore, potentiate the antibioticactivity of carbapenem antibiotics. Renal dehydropeptidase activity wasfirst described by M. Bergmann and H. Schleich, Z. Physiol. Chem., 205,65 (1932); see also B. J. Campbell et al., Biochim. Biophys. Acta., 118,371 (1966) and references therein.

In order to demonstrate the ability of the compounds of Formula I tosuppress the action of the renal dipeptidase enzyme, an in vitro screenprocedure was followed. This measured the ability of compounds toinhibit hydrolysis of glycyldehydrophenylalanine (GDP) by a solubilizedpreparation of dipeptidase isolated from hog kidneys. The procedure isas follows: to a 1 ml system containing 50 mM "MOPS"(3-(N-morpholino)propanesulfonic acid) buffer, pH 7.1, is added 5 μg oflyophilized enzyme, and the test compound at a final concentration of0.1 mM. After a five minute incubation at 37° C., GDP is added to afinal concentration of 0.05 mM. Incubation is continued for 10 minutes,at 37° C. and hydrolysis of GDP is measured by the change in opticaldensity with time at 275 nm. Inhibition of the enzyme is gauged bycomparison to a standard run containing no inhibitor and is expressed asthe inhibitor binding constant, K_(i). This is the concentration of theinhibitor which achieves 50% inhibition of enzyme.

The table below summarizes some representative data with compounds ofthis invention.

    ______________________________________                                        RENAL DEHYDROPEPTIDASE I INHIBITION                                           ______________________________________                                         ##STR7##                                                                     Stereochemistry                                                               of methyl   R.sub.2 (DL)    Ki (nM)                                           ______________________________________                                        DL          methyl          10                                                L           methyl          10                                                D           methyl          140                                               DL          n-butyl         4                                                 L           phenylpropyl    27                                                D           phenylpropyl    1000                                              DL          4-pyridylpropyl 12                                                ______________________________________                                         ##STR8##                                                                     Stereochemistry                                                               of methyl   R.sub.5      E/Z    Ki (nM)                                       ______________________________________                                        D           H            --     230                                           L           H            --     27                                            DL          n-pentyl     mixt.  5.8                                           DL          phenethyl    Z      16                                            DL          phenethyl    E      7                                             ______________________________________                                    

The in vivo effectiveness of DHP inhibitors to increase the metabolicstability of carbapenem antibiotics can be demonstrated by measuring theurinary recovery of such antibiotics in the presence and absence ofcoadministered dehydropeptidase inhibitor. For example, see F. M. Kahanet al., J. Antimicrobial Chemotherapy, 12, Suppl. D, 1-35 (1983). It isalso possible to observe this potentiation by measuring the dosagerequired to treat infections in animals with a dehydropeptidasesusceptible antibiotic alone or in combination with a dehydropeptidaseinhibitor.

For administration, the compositions of the invention can also containother conventional pharmaceutically acceptable compounding ingredients,as necessary or desired. Such ingredients are generally referred to ascarriers or diluents. Conventional procedures for preparing suchcompositions in appropriate dosage forms can be utilized. Whatever thedosage form, it will contain a pharmaceutically effective amount of thecompounds of the invention.

The present compositions can be administered parenterally and this ispreferred when they are used in combination with a carbapenem antibioticsuch as imipenem. They may also be administered orally. The compounds ofthis invention may also be used to treat topical antibacterialinfection. Therefore, these compounds may be presented in a number ofappropriate dosage forms; e.g., tablets, capsules, suspensions,solutions, and the like, for oral administration; solutions,suspensions, emulsions, and the like, for parenteral administration;solutions for intravenous administration; and ointments, transdermalpatches, and the like, for topical administration.

Compositions intended for oral use may be prepared according to anymethod known to the art for the manufacture of pharmaceuticalcompositions and such compositions may contain one or more agentsselected from the group consisting of sweetening agents, flavoringagents, coloring agents and preserving agents in order to providepharmaceutically elegant and palatable preparation. Tablets containingthe active ingredient in admixture with non-toxic pharmaceuticallyacceptable excipients may also be manufactured by known methods. Theexcipients used may be for example, (1) inert diluents such as calciumcarbonate, sodium carbonate, lactose, calcium phosphate or sodiumphosphate; (2) granulating and disintegrating agents such as cornstarch, or alginic acid; (3) binding agents such as starch, gelatin oracacia, and (4) lubricating agents such as magnesium stearate, stearicacid or talc. The tablets may be uncoated or they may be coated by knowntechniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate may be employed. They may also becoated by the techniques described in U.S. Pat. Nos. 4,256,108;4,160,452; and 4,265,874 to form osmotic therapeutic tablets forcontrolled release.

In some cases, formulations for oral use may be in the form of hardgelatin capsules wherein the active ingredient is mixed with an inertsolid diluent, for example, calcium carbonate, calcium phosphate orkaolin. They may also be in the form of soft gelatin capsules whereinthe active ingredient is mixed with water or an oil medium, for examplepeanut oil, liquid paraffin, or olive oil.

Aqueous suspensions normally contain the active materials in admixturewith excipients suitable for the manufacture of aqueous suspensions.Such excipients may be

(1) suspending agents such as sodium carboxymethylcellulose,methylcellulose, hydroxypropylmethylcellulose, sodium alginate,polyvinylpyrrolidone, gum tragacanth and gum acacia;

(2) dispersing or wetting agents which may be

(a) a naturally-occurring phosphatide such as lecithin,

(b) a condensation product of an alkylene oxide with a fatty acid, forexample, polyoxyethylene stearate,

(c) a condensation product of ethylene oxide with a long chain aliphaticalcohol, for example, heptadecaethyleneoxycetanol,

(d) a condensation product of ethylene oxide with a partial esterderived from a fatty acid and a hexitol such as polyoxyethylene sorbitolmonooleate, or

(e) a condensation product of ethylene oxide with a partial esterderived from a fatty acid and a hexitol anhydride, for examplepolyoxyethylene sorbitan monooleate.

The aqueous suspensions may also contain one or more preservatives, forexample, ethyl or n-propyl p-hydroxybenzoate; one or more coloringagents; one or more flavoring agents; and one or more sweetening agentssuch as sucrose or saccharin.

Oily suspension may be formulated by suspending the active ingredient ina vegetable oil, for example arachis oil, olive oil, sesame oil orcoconut oil, or in a mineral oil such as liquid paraffin. The oilysuspensions may contain a thickening agent, for example beeswax, hardparaffin or cetyl alcohol. Sweetening agents and flavoring agents may beadded to provide a palatable oral preparation. These compositions may bepreserved by the addition of an antioxidant such as ascorbic acid.

Dispersible powders and granules are suitable for the preparation of anaqueous suspension. They provide the active ingredient in admixture witha dispersing or wetting agent, a suspending agent and one or morepreservatives. Suitable dispersing or wetting agents and suspendingagents are exemplified by those already mentioned above. Additionalexcipients, for example, those sweetening, flavoring and coloring agentsdescribed above may also be present.

The pharmaceutical compositions of the invention may also be in the formof oil-in-water emulsions. The oily phase may be a vegetable oil such asolive oil or arachis oils, or a mineral oil such as liquid paraffin or amixture thereof. Suitable emulsifying agents may be (1)naturally-occurring gums such as gum acacia and gum tragacanth, (2)naturally-occurring phosphatides such as soy bean and lecithin, (3)esters or partial esters derived from fatty acids and hexitolanhydrides, for example, sorbitan monooleate, (4) condensation productsof said partial esters with ethylene oxide, for example, polyoxyethylenesorbitan monooleate. The emulsions may also contain sweetening andflavoring agents.

Syrups and elixirs may be formulated with sweetening agents, forexample, glycerol, propylene glycol, sorbitol or sucrose. Suchformulations may also contain a demulcent, a preservative and flavoringand coloring agents.

The pharmaceutical compositions may be in the form of a sterileinjectable aqueous or oleagenous suspension. This suspension may beformulated according to known methods using those suitable dispersing orwetting agents and suspending agents which have been mentioned above.The sterile injectable preparation may also be a sterile injectablesolution of suspension in a non-toxic parenterally-acceptable diluent orsolvent, for example as a solution in 1,3-butane diol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution and isotonic sodium chloride solution. In addition,sterile, fixed oils are conventionally employed as a solvent orsuspending medium. For this purpose any bland fixed oil may be employedincluding synthetic mono- or diglycerides. In addition, fatty acids suchas oleic acid find use in the preparation of injectibles.

For topical use, creams, ointments, jellies, solutions or suspensions,etc., containing the compositions of the invention are employed.

Treatment dosage for human beings can be varied as necessary. Generally,oral dosages of the antibacterial compounds of this invention when givenorally are in the range 250 mg to 4 g per patient given 3-4 times daily.The intravenous or intramuscular dosages are 100 mg to 1 g given 3-4times daily. When the compounds of the invention are given intravenouslyor intramuscularly to potentiate carbapenem antibiotics such as imipenemthey are given in combination with the antibiotic in amounts of 0.1-10mg/kg/day.

The amount of active ingredient that may be combined with the carriermaterials to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration. For example, aformulation intended for oral administration may contain, for example,from 100 mg to 2000 mg of active agent compounded with an appropriateand convenient amount of carrier material which may vary from about 5 toabout 95 percent of the total composition.

The amount of active ingredient that may be combined with the carriermaterials to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration.

It will be understood, however, that the specific dose level for anyparticular patient will depend upon a variety of factors including theactivity of the specific compound employed, the age, body weight,general health, sex, diet, time of administration, route ofadministration, rate of excretion, drug combination and the severity ofthe particular disease undergoing therapy.

The compounds of Formula 1 can be prepared by the methods shown in thefollowing Reaction Scheme wherein R¹, R² and R³ are as defined aboveunless otherwise indicated.

As will be evident to those skilled in the art and as demonstrated inthe Examples hereinafter, reactive groups not involved in the reactions,such as amino, carboxy, mercapto, etc., may be protected by methodsstandard in peptide chemistry prior to the coupling reactions andsubsequently deprotected to obtain the desired products. Cbz refers tocarbobenzyloxy. ##STR9##

The Cbz aminoalkylphosphonous acids (1) can be prepared according toprocedures described by P. A. Bartlett et al. (J. Amer. Chem. Soc. 106,4282-4283 (1984)) and E. K. Baylis et al. (J. Chem. Soc. Perkin Trans.1, 2845-2853 (1984)) and can be resolved to give optically activematerials by the method of Baylis (reference above) both methods herebyincorporated by reference. Compounds derived from both the opticallyactive and racemic materials are claimed in the present invention.

The protected aminoalkylphosphonous acid (1) is esterified with eitherdiazomethane or triethylorthoformate to give the methyl or ethyl ester(2) which is deprotonated with either sodium methoxide or ethoxide inthe corresponding alcohol and treated with the appropriately substitutedacrylate to give (4), the protected form of Formula I. The acrylates canbe prepared by procedures obtained by J. Harley-Mason in Tetrahedron 36,1036-1070 (1980), hereby incorporated by reference.

Compound 4 can be alternatively synthesized by alkylation of theprotected aminoalkylphosphonous acid (1) with appropriately substituted3-halopropionates or acrylates in the presence of atrialkylsilylchloride such as trimethylsilylchloride and a tertiaryamine such as triethylamine according to the general methods of J. K.Thottathil et al. (Tetrahedron Lett. 25, 4737-40, 4741-44 (1984), herebyincorporated by reference.

The phosphinic acid 3 may be esterified by diazomethane to give compound4. ##STR10##

Compound 4 is converted to formula I by two standard routes. Thecarbobenzyloxy group can be removed by either hydrogenation in analcohol such as ethanol with a catalyst such as Pd/C, or by cleavagewith HBr in acetic acid. Subsequent ester hydrolysis in concentrated HClprovides after treating with propylene oxide, for example, compounds offormula I (R₃ =H). The carboxyester (R₃ =alkyl) can be isolated bydesalting ester hydrobromide 6. The phosphinic ester (R₄ =alkyl) can beisolated by selective hydrolysis of carboxyester 5. ##STR11##

This alternative route involves a conjugate addition of the phosphonousester under the conditions previously outlined totrimethyl-2-phosphonoacrylate. The subsequent anion is then trapped withan aldehyde yielding the dehydro compound as a mixture of E and Zisomers. This same intermediate can be prepared by alkylation of theprotected aminoalkylphosphonous acid with substituted2-bromomethylacrylates under conditions reported by J. K. Thottathil, etal. Tetrahedron Lett. 25, 4737-40, 4741-44 (1984), hereby incorporatedby reference. The olefin may then be selectively reduced usinghomogenous catalysis. For instance, one may use a (COD)₂ RhCl₂ complexwith an organophosphine ligand in methanol to give compound I which canbe further elaborated by procedures already outlined.

Chiral organophosphine ligands such as(-)2,3-0-isopropylidene-2,3-dihydroxy-1,4-bis (diphenylphosphino)butane,((-) DIOP), may be used in order to produce the S or R stereoisomers atR₂ in high enantiomeric excess.

Preferred diastereomers for antibacterial activity correspond to theabsolute stereochemistry of D-Ala-D-Ala at the carbons bearing R¹ and R²and are in general described as D(S),D(R) or S,R-diastereomers and R₅ isE or Z.

Preferred diastereomers for dehydropeptidase inhibition correspond toL-amino acids (R stereochemistry) at the carbon bearing R₁.Stereochemistry at R₂ may correspond to either D- or L-amino acids forgood activity (R or S). The stereochemistry at R₅ in dehydro analogs canbe either E or Z and preferably is Z.

When both antibacterial and dehydropeptidase activities are desired thecarbon atom bearing R₁ is preferred in the DL-form.

Preferred diastereomers are isolated by chromatography or resolution ofintermediates or the end products or their salts.

Racemates may be separated by standard methods including by the use ofoptically active amines and acids as resolving agents. The followingexamples are illustrative of the subject invention and should not beconstrued as being limitations on the scope or input of the instantinvention.

EXAMPLE 1 Preparation of 1-Benzyloxycarbonylaminoethylphosphonous acidmethyl ester ##STR12##

1-Benzyloxycarbonylaminoethylphosphonous acid, prepared by the method ofE. K. Baylis et al. [J. Chem. Soc., Perkin Trans, 2845-2853 (1984)] wasesterified with diazomethane in an ether solution prepared by a methodof F. Arndt [Organic Syn. Coll. V. II 165-167 (1943)]. The compound waspurified by standard chromatography on silica gel.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.51

NMR (CDCl₃, TMS) δ 1.2 and 1.5 (2d, 3H); 2.2 and 10.1 (d, 1H); 3.6 (d,3H); 3.9 (m, 1H); 5.0 (s, 2H); 6.0-6.6 (overlapping doublets, 1H); 7.2(s, 5H).

EXAMPLE 2 1-Aminoethyl-[2-carboxy-1-ethyl]phosphinic acid ##STR13##

To a stirred solution of 0.36 gm (0.0014 mol) of1-benzyloxycarbonylaminoethylphosphonous acid methyl ester in 3 ml ofmethanol at 0° C. was added a solution of sodium methoxide in methanol(0.77 ml of a 2N solution) dropwise over 10 minutes whereupon was thenadded methyl acrylate 0.126 ml (0.0014 mol). The reaction mixture wasstirred 30 minutes at 0° C. and 4 hours at room temperature whereupon itwas diluted with 1N HCl. The mixture was extracted twice with ethylacetate. The organic fractions were dried over sodium sulfate, filteredthrough magnesium sulfate and evaporated in vacuo. The product mixturewas purified by chromatography (silica, 9:1, ethylacetate:acetonitrile)to give 0.34 gm ofmethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-1-ethyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.47

NMR (CDCl₃) δ 1.4 (m, 3H); 2.00-2.2 (m, 2H); 2.5-2.7 (m, 2H); 3.7 (s,3H); 3.7-3.9 (m, 3H); 4.1 (quintet, 1H); 5.1 (s, 2H); 5.2 (d, 1/2H);5.55 (d, 1/2H); 7.4 (s, 5H).

Elem. Anal. Calc'd for C₁₅ H₂₂ NO₆ P.1/2H₂ O N, 3.97; C, 51.13; H, 6.25Found: N, 3.64; C, 50.78; H, 6.46

mass spectrum=M⁺ 343

300 mg of the aforementioned intermediate was subsequently stirred 12hours in a solution of 30% HBr in acetic acid (5 ml). The reactionmixture was evaporated in vacuo, dissolved in 5 ml of H₂ O and washedtwice with diethylether. The aqueous layer was evaporated in vacuo,dissolved in 5 ml of concentrated HCl and stirred 3 days at 50° C. andwas subsequently evaporated in vacuo. The hydrochloride salt wasdissolved in 1 ml of methanol and diluted with 20 ml of propylene oxide.A solid precipitated out which was filtered and washed with ether togive the title compound as a hygroscopic glass.

TLC (silica, 1:1:1:1, n-butanol:H₂ O:acetic acid: ethyl acetate) R_(f)=0.28

NMR (D₂ O) δ 1.35-1.5 (2 overlapping d, 3H); 1.85-2.0

(m, 2H); 2.55-2.65 (ABQ, 2H); 3.25-3.35 (m,1 H).

Elem. Anal. Calc'd for C₅ H₁₂ NO₄ P.1/2H₂ O N, 7.19; C, 30.84; H, 6.68Found: N, 6.79; C, 30.87; H, 6.70

mass spectrum (FAB) M+1, 182

EXAMPLE 3 1-Aminoethyl-(2-carboxy-1-propyl)phosphinic acid ##STR14##

By the same methods used for Example 2 and using methylmethacrylate wasmade methyl1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-1-propyl]phosphinate.

NMR (CDCl₃) δ 1.2-1.4 (m, 6H); 1.7-1.9 (m, 1H); 2.2-2.4 (m, 1H);2.8-2.95 (m, 1H); 3.7(s, 3H); 3.65-3.8 (m, 3H); 4.0-4.2 (m, 1H); 5.15(s, 2H); 5.4-5.55 (m, 1H); 7.35 (s, 5H).

Elem. Anal. Calc'd for C₁₆ H₂₄ N06P N, 3.92; C, 53.78; H, 6.72 Found: N,3.87; C, 53.81; H, 6.47

The compound was then deprotected by procedures used in Example 2 toprovide 1-aminoethyl(2-carboxy-1-propyl)phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol, water, acetic acid, ethyl acetate)R_(f) =0.4

NMR (D₂ O) δ 1.25 (d, 3H); 1.35-1.45 (overlapping d, 3H); 1.7-1.9 (m,1H); 2.1-2.25 (m, 1H); 2.75-2.9 (m, 1H); 3.3-3.45 (m, 1H).

Elem. Anal. Calc'd for C₆ H₁₄ NO₄ P.3/4H₂ O N, 6.71; C, 34.54; H, 6.76Found: N, 6.61; C, 34.84; H, 6.69

Methyl Carboxyesters

Esters of the carboxylic acid functionality have been made for all theexamples and were prepared by dissolving the aminosubstitutedalkyl-(2-carboxysubstituted alkyl)phosphonic acid in the appropriatealcohol (methanol if one wants the methyl ester). The solution is thensaturated with HCl gas or treated with a few drops of sulfuric acid andthen stirred for 24 hours at which time the reaction is evaporated invacuo. The amine salt is then desalted with propylene oxide as inExample 2 to give the carboxyester of the afore described examples.

EXAMPLE 3A 1-Aminoethyl-(2-carbomethoxy-1-propyl)phosphinic acid##STR15##

A solution of 100 mg of 1-aminoethyl-(2-carboxy-1-propyl)phosphinic acidin methanol (5 ml) was cooled to 0° C. and saturated with HCl gas. Thesealed reaction mixture was then stirred 12 hours at room temperaturewhereupon the methanol was removed in vacuo to provide the titlecompound as a hydrochloride salt which was desalted via the procedure,in Example 2 using propylene oxide to provide the title compound. (80mg).

NMR (D₂ O) δ 1.2 (d, 3H); 1.3 (d, 1.5H); 1.5 (d, 1.5H); 1.8-3.0 (m, 3H);3.3-3.7 (m, 1H); 3.6 (s, 3H).

Mass spectrum (M³⁰ +1) 210.

EXAMPLE 4 1-Aminoethyl-[2-carboxy-1-n-butyl]phosphinic acid ##STR16##

By the methods previously outlined in Example 2 but usingmethyl-2-ethylacrylate was mademethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-1-n-butyl]phosphinate

NMR (CDCl₃) δ 0.8 (overlapping, 3H); 1.2, 1.5 (2d, 3H); 1.4-3.2 (m, 5H);3.7 (s, 3H); 3.7 (d, 3H); 3.8-4.3 (m, 1H); 5.1 (s, 2H); 5.8 (d, 7.5H);6.3 (d, 0.5H); 7.3 (s, 5H).

The above compound was deprotected by aforementioned methods to produce1-aminoethyl-[2-carboxy-1-n-butyl]phosphinic acid as a hygroscopicglass.

TLC (silica, 1:1:1:1, n-butenol, water, acetic acid, ethyl acetate)R_(f) =0.37

NMR (D₂ O) δ 0.9 (t, 3H); 1.3-1.5 (2, 3H); 1.55-1.8 (m, 3H); 1.95-2.1(m, H); 1.6-1.75 (m, 1H); 3.2-3.3 (m, 1H).

Elem. Anal. Calc'd for C₇ H₁₆ NO₄ P.2H₂ O N, 6.16; C, 37.00; H, 7.04Found: N, 5.95; C, 36.92; H, 7.42

Mass spectrum: M+H 210.

EXAMPLE 5 1-Aminoethyl-[2-carboxy-1-n-pentyl]phosphinic acid ##STR17##

By methods outlined in Example 2 and using methyl-2-propyl acrylate wasprepared methyl1-benzyl-oxycarbonylaminoethyl-[2-carbomethoxy-1-n-pentyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.45

NMR (CDCl₃) δ 0.9 (t, 3H); 1.25, 1.5 (2d, 3H); 1.4-3.0 (m, 7H); 3.65(overlapping s, 3H); 3.7 (d, 3H); 1.6-4.4 (m, 1H); 5.0 (s, 2H); 5.8 (d,0.5H); 6.4 (d, 0.5H); 7.3 (s, 5H).

Elem. Anal. Calc'd for C₁₈ H₂₈ NO₆ P.1/4H₂ O N, 3.59; C, 55.45; H, 7.18Found: N, 3.66; C, 55.42; H, 7.10

Mass spectrum M⁺ 385

By the earlier reported methods, the above intermediate was deprotectedto produce 1-aminoethyl[2-carboxy-1-n-pentyl]phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol, H₂ O, acetic acid, ethyl acetate) R_(f)=0.4

NMR (D₂ O) δ 1.85 (t, 3H); 1.2-1.5 (m, 7H); 1.5-1.9 (m, 4H); 1.9-2.1 (m,1H); 2.6-2.8 (m, 1H); 3.2-3.35 (m, 1H)

Mass spectrum M-H 222.

Elem. Anal. Calc'd for C₈ H₁₈ NO₄ P.1H₂ O N, 5.80; C, 39.83; H, 7.46Found: N, 5.96; C, 39.48; H, 7.51

EXAMPLE 6 1-Aminoethyl-[2-carboxy-1-n-hexyl]phosphinic acid ##STR18##

By methods outlined in Example 2 and using methyl-2-n-butyl acrylate wasprepared methyl1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-1-n-hexyl]phosphonic acid.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.54

NMR (CDCl₃) δ 0.9 (t, 3H); 1.1-3.2 (m, 12H); 3.6 (s, 3H); 3.6 (d, 3H);3.7-4.3 (m, 1H); 5.0 (s, 2H); 5.5 (d, 0.5H); 5.9 (d, 0.5H); 7.3 (s, 5H).

Mass spectrum M⁺ 399

This intermediate was converted by earlier reported methods to1-aminoethyl-[2-carboxy-1-n-hexyl]phosphonic acid.

NMR (D₂ O) δ 1.85 (t, 3H); 1.15-1.50 (m, 7H); 1.55-1.8 (m, 3H); 1.95-2.1(m, 1H); 2.6-2.8 (m, 1H); 3.15-3.3 (m, 1H)

Elem. Anal. Calc'd for C₉ H₂₀ NO₄ P.1/4H₂ O N, 5.79; C, 44.72; H, 8.28Found: N, 5.57; C, 44.40; H, 8.08

Mass spectrum M⁺ 238

EXAMPLE 7 1-Aminoethyl-[2-carboxy-4-methyl-1-n-pentyl]phosphinic acid##STR19##

By methods outlined in Example 2 and using methyl-2-isobutyl acrylatewas mademethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-4-methyl-1-n-pentyl]phosphinate.

NMR (D₂ O) 1.9 (overlapping d, 6H); 1.5-3.2 (m, 9H); 4.6 (d, 3H);3.8-4.3 (m, 1H); 5.1 (s, 2H); 5.5 (d, 0.5H); 5.9 (d, 0.5H); 7.2 (s, 5H).

Elem. Anal. Calc'd for C₁₉ H₃₀ NO₆ P.1/4H₂ O N, 3.46; C, 56.51; H, 7.44Found: N, 3.56; C, 56.34; H, 7.47

Mass spectrum M⁺ 400

The intermediate was converted to1-aminoethyl-[2-carboxy-4-methyl-1-n-pentyl]phosphinic acid by methodsreported in Example 2.

NMR (CDCl₃) δ 1.9 (overlapping d, 6H); 1.3-1.65 (m, 6H); 1.75(overlapping t, 1H); 1.9-2.1 (m, 1H); 2.7-2.9 (m, 1H); 3.15-3.35 (m,1H).

Elem. Anal. Calc'd for C₉ H₂₀ NO₄ P.1H₂ O N, 5.49; C, 42.35; H, 7.84Found: N, 5.55; C, 42.79; H, 8.03

Mass spectrum M⁻ 236

EXAMPLE 8 1-Aminoethyl-[2-carboxy-5-cyclohexyl-1-n-pentyl]phosphinicacid ##STR20##

By methods outlined in Example 2 and usingmethyl-2-[3-cyclohexyl-1-propyl]acrylate was preparedmethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-5-cyclohexyl-1-n-pentyl]phosphinate.

NMR (CDCl₃) δ 0.8-3.1 (m, 23H); 3.6 (s, 3H); 3.6 (d, 3H); 3.6-4.2 (m,1H); 5.0 (s, 2H); 5.2 (d, 0.5H); 5.5 (d, 0.5H); 7.2 (s, 5H).

Elem. Anal. Calc'd for C₂₄ H₃₈ NO₆ P N, 3.00; C, 61.66; H, 8.19 Found:N, 3.19; C, 61.32; H, 8.08

Mass spectrum M⁺ 468

This compound was converted by methods in Example 2 to1-aminoethyl-[2-carboxy-5-cyclohexyl-1-n-pentyl]phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol:H₂ O:acetic acid:ethyl acetate) R_(f)=0.66

NMR (D₂ O) δ 0.8-3.2 (m, 23H); 3.7-4.2 (m, 1H).

Mass spectrum M⁺ H 304

EXAMPLE 9 1-Aminoethyl-[2-carboxy-1-nonyl]phosphinic acid ##STR21##

Methyl-1-Benzyloxycarbonylaminoethyl-[2-carbomethoxy-1-nonyl]phosphinatewas prepared in 60% yield by the method described in Example 2.

NMR (CDCl₃, 300 MHz): δ 0.9 (m, 3H); 1.2-1.4 (m, 13H); 1.6 (m, 2H); 1.8(m, 1H); 2.2 (m, 1H); 2.8 (m, 1H); 3.7 (m, 6H); 4.1 (m, 1H); 5.0-5.3 (m,3H); 7.4 (br s, 5H).

Elem. Anal. Calc'd for C₂₂ H₃₆ NO₆ P N, 3.17; C, 59.85; H, 8.22 Found:N, 3.06; C, 59.94; H, 8.03

Mass spectrum (pos. ion FAB): M⁺ H 442 (100%)

Analytical TLC: R_(f) =0.69 (ethyl acetate/acetonitrile/methanol,9:1:0.5) ##STR22##

The title compound was prepared by the procedure described in Example 2.

NMR (D₂ O, 300 MHz): δ 0.8 (t, 3H); 1.3-1.5 (m, 13H); 1.5-1.8 (m, 3H);2.0 (m, 1H); 2.7 (m, 1H); 3.2 (m, 1H).

Elem. Anal. Calc'd for C₁₂ H₂₆ NO₄ P: N, 5.01; C, 51.60; H, 9.38 Found:N, 5.03; C, 50.94; H, 9.02

Mass spectrum (pos. ion FAB): M⁺ H 280 (100%)

Analytical TLC: R_(f) =0.67 (ethyl acetate/1-butanol/acetic acid/water,1:1:1:1)

EXAMPLE 10 1-Aminoethyl-[2-carboxy-3-phenyl-1-n-propyl]phosphinic acid##STR23##

By methods used in Example 2 and employing methyl-2-benzylacrylate wasmademethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-3-phenyl-1-n-propyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.61

NMR (CDCl₃) δ 1.1-1.5 (2d, 3H); 1.7-3.1 (m, 5H); 3.4-3.6 (m, 6H);3.7-4.3 (m, 1H); 5.0 (s, 2H); 5.6 (d, 0.5H); 6.1 (d, 0.5H); 7.0 (bs,5H); 7.2 (s, 5H).

Elem. Anal. Calc'd for C₂₂ H₂₈ NO₆ P.1/4H₂ O N, 3.20; C, 60.34; H, 6.44Found: N, 2.78; C, 60.17; H, 6.54

Mass spectrum M⁺ 433

This compound was converted by methods in Example 2 to1-aminoethyl-[2-carboxy-3-phenyl-1-n-propyl]phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol:H₂ O:acetic acid:ethyl acetate) R_(f)=0.42

NMR (D₂ O) δ 1.25-1.45 (m, 3H); 1.7-1.9 (m, 1H); 2.0-2.15 (m, 1H);2.8-3.1 (m, 3H); 3.1-3.3 (m, 1H); 7.2-7.45 (2 overlapping s, 10H).

Elem. Anal. Calc'd for C₁₂ H₁₈ NO₄ P.1H₂ O N, 4.84; C, 49.82; H, 6.22Found: N, 4.61; C, 49.45; H, 6.32

Mass spectrum M-1 270.

EXAMPLE 11 1-Aminoethyl-[2-carboxy-3-phenyl-1-n-butyl)phosphinic acid##STR24##

By methods used in Example 2 and employing methyl-2-phenethylacrylatewas mademethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-4-phenyl-1-n-butyl]-phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.57

NMR (CDCl₃) δ 1.2 (d, 1.5H); 1.5 (d, 1.5H); 1.6-3.1 (m, 7H); 3.6 (s,3H); 3.6 (d, 3H); 3.7-4.3 (m, 1H); 5.0 (s, 2H); 5.4 (d, 0.5H); 5.9 (d,0.5H); 7.1 (s, 5H); 7.3 (s, 5H).

Mass spectrum: M+1 448

This compound was converted by methods in Example 2 to1-aminoethyl-[2-carboxy-4-phenyl-1-n-butyl]phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol:H₂ O:acetic acid:ethyl acetate) R_(f)=0.30

NMR (D₂ O) δ 1.35-1.5 (overlapping d, 8H); 1.85-2.05 (m, 3H); 2.1-2.3(m, 1H); 3.3-3.45 (m, 8H); 7.2-7.45 (m, 10H).

Elem. Anal. Calc'd for C₁₃ H₂₀ NO₄ P.1/4H₂ O N, 4.83; C, 53.88; H, 6.90Found: N, 4.62; C, 53.78; H, 7.19

Mass spectrum M⁺ -1 284.

EXAMPLE 12 1-Aminoethyl-[2-carboxy-5-phenyl-1-n-pentyl]phosphinic acid##STR25##

By methods using in Example 2 and employingmethyl-2-(3-phenyl-1-propyl)acrylate was preparedmethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-5-phenyl-1-n-pentyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.44

NMR (CDCl₃) δ 1 0.2 (d, 1.5H); 1.5 (d, 1.5H); 1.5-3.2 (m, 9H); 3.6 (d,3H); 3.7 (s, 3H); 3.7-4.2 (m, 1H); 5.0 (s, 2H); 5.5 (d, 0.5H); 5.9 (d,0.5H); 7.1 (s, 5H); 7.3 (s, 5H).

This compound was converted by methods in Example 2 to1-aminoethyl-[2-carboxy-5-phenyl-1-n-pentyl]phosphinic acid.

TLC (silica, 1:1:1:1, n-butanol:H₂ O:acetic acid: ethyl acetate) R_(f)=0.32

NMR (D₂ O) δ 1.3-1.4 (2 overlapping d, 3H); 1.4-1.7 (m, 5H); 1.85-2.0(m, 1H); 2.1-2.3 (m, 1H); 2.45-2.6 (m, 1H); 2.6-2.8 (m, 1H); 3.45-3.55(m, 1H); 7.1-7.3 (m, 10H).

Mass spectrum: (M+1) 266

Elem. Anal. Calc'd for C₁₄ H₂₂ NO₄ P.1.5H₂ O N, 4.413 C, 51.53; H, 7.66Found: N, 4.04; C, 51.35; H, 7.41

EXAMPLE 13 1-Aminoethyl-[2,3-dicarboxy-1-n-propyl]phosphinic acid##STR26##

By methods used in Example 2 and employingmethyl-2-t-butoxycarbonylmethylacrylate was preparedmethyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-3-butoxycarbonyl-1-propyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.58

NMR (CDCl₃) δ 1.2 (d, 1.5H); 1.5 (d, 1.5H); 1.4 (s, 9H); 1.8-3.2 (m,5H); 1.625 (s, 3H); 1.64 (d, 3H); 1.8-3.3 (m, 1H); 5.05 (s, 2H); 5.3 (d,0.5H); 5.7 (d, 0.5H); 7.2 (s, 5H).

Elem. Anal. Calc'd for C₂₁ H₃₂ NO₈ P.1/4H₂ O N, 3.03; C, 54.60; H, 6.98Found: N, 3.15; C, 54.65; H, 6.94

Mass spectrum M⁺ 457.

This compound was converted by methods in Example 2 to1-aminoethyl-[2,3-dicarboxy-1-n-propyl]phosphinic acid.

NMR (D₂ O) δ 1.3 (d, 1.5H); 1.55 (d, 1.5H); 1.8-2.4 (m, 2H); 2.6-2.8 (m,2H); 2.9-3.7 (m, 3H).

Mass spectrum: (M⁺ -1) 238.

EXAMPLE 14 1-Aminoethyl-[2,5-dicarboxy-1-n-pentyl]phosphinic acid##STR27##

By methods used in Example 2 and employingdimethyl-2-(3-carboxy-1-propyl)acrylate was preparedtrimethyl-1-benzyloxycarbonylaminoethyl-[2,5-dicarboxy-1-n-pentyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.48

NMR (CDCl₃) δ 1.2-3.1 (m, 12H); 3.55 (s, 3H); 3.6 (d, 3H); 3.7-4.2 (m,1H); 5.0 (s, 2H); 5.3 (d, 0.5H); 5.75 (d, 0.5H); 7.2 (s, 5H).

Mass spectrum: M⁺ 443

This compound was converted by methods in Example 2 to1-aminoethyl-[2,5-dicarboxy-1-n-propyl]phosphinic acid.

NMR (D₂ O) δ 1.1-2.8 (m, 12H); 3.1-3.6 (m, 1H).

Mass spectrum: (M⁺ +1) 268.

EXAMPLE 15 1-Aminoethyl-[2-carboxy-6-hydroxy-1-n-hexyl]phosphinic acid##STR28##

By methods used in Example 2 and employingmethyl-2-[4-t-butyldimethylsilyloxy-1-n-butyl]acrylate was preparedmethyl-1-benzyloxycarbonylaminoethyl-[2-carboxy-6-t-butyldimethylsilyloxy-1-n-butyl]phosphinate.

TLC (silica, 9:1, ethyl acetate:acetonitrile) R_(f) =0.59

NMR (CDCl₃) δ 0.0 (s, 6H); 0.9 (s, 9H); 1.1-3.2 (m, 12H); 1.4-1.7 (m,9H); 1.7-4.3 (m, 1H); 5.0 (s, 2H); 5.4 (d, 0.5H); 5.8 (d, 6H); 7.2 (s,5H).

Mass spectrum: M⁺ 529

This compound was converted by methods in Example 2 to1-aminoethyl-[2-carboxy-6-hydroxy-1-n-hexyl]phosphinic acid.

NMR (D₂ O) δ 1.15-3.2 (m, 12H); 3.25-3.65 (m, 3H).

Mass spectrum: (M⁺ +1) 264.

EXAMPLE 16 1-Aminoethyl-[2-carboxy-4-(1-naphthyl)-1-n-butyl]phosphinicacid ##STR29##

Methyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-4-(1-naphthyl)-1-n-butyl]phosphinatewas prepared in 65% yield by the method described in Example 2.

NMR (CDCl₃, 300 MHz); δ 1.4 (q, 3H); 1.9-2.2 (m, 3H); 2.3 (m, 1H); 3.0(m, 3H); 3.7 (m, 6H); 4.1 (m, 1H); 5.1 (m, 3H); 7.2-8.0 (m, 12H).

Elem. Anal. Calc'd for C₂₇ H₃₂ NO₆ P.1/2H₂ O N, 2.76; C, 63.96; H, 6.51Found: N, 2.42; C, 63.85; H, 6.33

Mass spectrum (EI): M⁺ 497 (10%).

Analytical TLC R_(f) =0.58 (ethyl acetate/acetonitrile/methanol 9:1:0.5)##STR30##

The title compound was prepared by the procedure described in Example 2.

NMR (D₂ O, 300 MHz): δ 1.4 (q, 3H); 1.8 (m, 1H); 2.1 (m, 3H); 2.8 (m,1H); 3.1 (m, 3H); 7.4-8.1 (m, 7H).

Elem. Anal. Calc'd for C₁₇ H₂₃ NO₄ P.3/2H₂ O N, 3.86; C, 56.30; H, 6.90Found: N, 3.66; C, 56.23; H, 6.71

Mass spectrum (neg. ion FAB): M-H 334 (25%).

Analytical TLC: R_(f) =0.67 (ethyl acetate/1-butanol/acetic acid/water1:1:1:1)

EXAMPLE 17 1-Aminoethyl-[2-carboxy-4-(2-naphthyl)-1-n-butyl]phosphinicacid ##STR31##

Methyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-4-(2-naphthyl)-1-n-butyl]phosphinatewas prepared in 75% yield by the method described in Example 2.

NMR (CDCl₃, 300 MHz): δ 1.4 (m, 3H); 1.8-2.1 (m, 3H); 2.3 (m, 1H); 2.7(m, 2H); 2.9 (m, 1H); 3.6-3.7 (m, 6H); 4.1 (m, 1H); 5.1-5.3 (m, 3H);7.3-7.8 (m, 12H).

Elem. Anal. Calc'd for C₂₇ H₃₂ NO₆ P.1/2H₂ O N, 2.76; C, 63.96; H, 6.51Found: N, 2.40; C, 63.79; H, 6.43

Mass spectrum (EI): M⁺ 497 (12%).

Analytical TLC: R_(f) =0.67 (ethyl acetate/acetonitrile/methanol9:1:0.5) ##STR32##

The title compound was prepared by the procedure described in Example 2.

NMR (D₂, 300 MHz): δ 1.3 (q, 3H); 1.8 (m, 1H); 2.1 (m, 3H); 2.8 (m, 3H);3.2 (m, 1H); 7.4-7.9 (m, 7H). Mass spectrum (pos. ion FAB): M+H 336(100%).

Analytical TLC: R_(f) =0.65 (ethyl acetate/1-butanol/acetic acid/water1:1:1:1)

EXAMPLE 18 1-Aminoethyl-[2-carboxy-5-(4-pyridyl)-1-n-pentyl]phosphinicacid ##STR33##

Methyl-1-benzyloxycarbonylaminoethyl-[2-carbomethoxy-5-(4-pyridyl)-1-n-pentyl]phosphinatewas prepared in 84% yield by the method described in Example 2.

NMR (CDCl₃, 300 MHz): δ 1.35 (q, 3H); 1.80 (m, 1H); 2.25 (m, 1H); 2.55(m, 1H); 2.6 (m, 5H); 2.80 (m, 1H); 3.6 (d, 3H); 3.7 (s, 3H); 4.1 (m,1H); 5.1 (d, 12 Hz, 0.5H); 5.1 (s, 2H); 5.7 (d, 12 Hz, 0.5H); 7.1 (d, 6Hz, 2H); 7.35 (br s, 5H); 8.5 (d, 6Hz, 2H).

Elem. Anal. Calc'd for C₂₃ H₃₁ N₂ O₆ P N, 6.06; C, 59.73; H, 6.76 Found:N, 5.99; C, 59.08; H, 6.73

Mass spectrum (pos. ion FAB): M⁺ H 463 (100%).

Analytical TLC: R_(f) =0.30 (ethyl acetate/acetonitrile/methanol9:1:0.5) ##STR34##

The title compound was prepared from the above compound by the methodsdescribed previously.

NMR (D₂ O, 300 MHz): δ 1.3 (q, 3H); 1.7 (m, 5H); 2.1 (m, 1H); 2.8 (m,1H); 3.0 (m, 2H); 3.2 (m, 1H); 7.9 (d, 8 Hz, 2H); 8.6 (d, 8 Hz, 2H).

Mass spectrum (pos. ion FAB): M+H 301 (100%).

Analytical TLC: R_(f) =0.15 (ethyl acetate/1-butanol/acetic acid/water,1:1:1:1)

EXAMPLE 19 1-L-Aminoethyl-(2-carboxy-1-propyl)phosphinic acid ##STR35##

By the same methods used for Example 2, but using1-(L)-benzyloxycarbonylaminoethylphosphous acid methyl ester and methylmethacrylate, was mademethyl-1-benzyloxycarbonyl-L-aminoethyl-[2-carbomethoxy-1-propyl]phosphinate.

TLC: (silica, 9:1, ethylacetate:acetonitrile) R_(f) =0.54.

NMR (CDCl₃): δ 1.2-1.5 (m, 6H); 1.7-1.9 (m, 1H); 2.2-2.4 (m, 1H);2.8-3.0 (m, 1H); 3.7 (s, 3H); 3.6-3.8 (d, 3H); 4.0-4.2 (m, 1H); 5.1 (s,2H); 5.2-5.4 (m, 1H); 7.3 (s, 5H).

Elem. Anal. Calc'd for C₁₆ H₂₄ NO₆ P.1/2H₂ O N, 3.82; C, 52.45; H, 6.60Found: N, 3.98; C, 52.76; H, 6.55

Mass spectrum: FAB (M+H)=358

The compound was deprotected by procedures used in Example 2 to provide1-L-aminoethyl-(2-carboxy-1-propyl)phosphinic acid.

TLC: (silica, 1:1:1:1, n-butanol, water, acetic acid, ethyl acetate)R_(f) =0.52

NMR (D₂ O): δ 1.25 (t, 3H); 1.3-1.5 (overlapping d, 3H); 1.7-1.9 (m,1H); 2.1-2.3 (m, 1H); 2.75-2.9 (m, 1H); 3.3-3.5 (m, 1H).

Elem. Anal. Calc'd for C₆ H₁₄ NO₄ P.1H₂ O N, 6.57; C, 33.81; H, 6.62Found: N, 6.51; C, 33.63; H, 6.39

Mass spectrum: FAB (M+H)=196

EXAMPLE 20 1-D-Aminoethyl-(2-carboxy-1-propyl)phosphinic acid ##STR36##

By the same methods used for Example 2, but using1-(D)-benzyloxycarbonylaminoethylphosphous acid methyl methacrylate, wasmademethyl-1-benzyloxycarbonyl-D-aminoethyl-[2-carbomethoxy-1-propyl]phosphinate.

TLC: (silica, 9:1, ethylacetate:acetonitrile) R_(f) =0.54. ##EQU1##

XL 300 NMR: δ 1.15-1.45 (m, 6H); 1.7-1.9 (m, 1H); 2.2-2.4 (m, 1H);2.8-3.0 (m, 1H); 3.7 (s, 3H); 3.55-3.8 (m, 3H); 4.0-4.2 (m, 1H);4.95-5.1 (m, 1H); 5.1 (s, 2H); 7.4 (s, 5H).

El. analysis: Calc. for C₁₆ H₂₄ NO₆ P. 1/2H₂ O N, 3.82; C, 52.46; H,6.60 Found: N, 4.04; C, 52.02; H, 6.50

Mass Spectrum: FAB (m+H)=358

The compound was deprotected by procedures used in Example 2 to provide1-D-aminoethyl-(2-carboxy-1-propyl)phosphinic acid.

TLC: (silica, 1:1:1:1, n-butanol, water, acetic acid, ethyl acetate)R_(f) =0.64.

NMR (D₂ O): δ 1.2 (d, 3H); 1.3-1.4 (2d, 3H); 1.65-1.8 (m, 1H) 2.05-2.2(m, 1H); 2.7-2.9 (m, 1H); 3.25-3.4 (m, 1H)

El. analysis: Calc. for C₆ H₁₄ NO₄ P. 1/4H₂ O N, 7.01; C, 36.10; H, 7.07Found: N, 6.70; C, 36.05; H, 6.99

Mass Spectrum: FAB (m+H)=1.96, (2m+H)=391

EXAMPLE 21 1-L-Aminoethyl-(2-carboxy-1-n-butyl)phosphinic acid ##STR37##

By the same methods used for Example 2, but using1-(L)-benzyloxyaminoethylphosphorus acid methyl ester andmethyl-2-ethacrylate, was mademethyl-1-benzyloxycarbonyl-L-aminoethyl-[2-carbomethoxy-1-n-butyl]phosphinate.

TLC: (silica, 9:1, ethylacetate:acetonitrile) R_(f) =0.54.

XL 300 NMR (CDCl₃): δ 0.8-1.0 (m, 3H); 1.2-1.45 (m, 3H); 1.5-1.7 (m,2H); 1.15-1.9 (m, 1H); 2.15-2.35 (m, 1H); 3.65-3.85 (m, 1H); 3.7 (s,3.H); 3.6-3.8 (m, 3H); 4.0-4.2 (m, 1H); 5.1 (s, 2H); 5.3-5.5 (m, 1H);7.35 (s, 5H).

El. analysis: Calc. for C₁₇ H₂₆ NO₆ P. 1/2H₂ O N, 3.68; C, 53.68; H,6.89 Found: N, 4.00; C, 53.80; H, 6.70.

Mass Spectrum: FAB (m+H)=372 ##EQU2##

The compound was deprotected by procedures used in Example 2 to provide1-L-aminoethyl-(2-carboxy-1-n-butyl)phosphinic acid.

TLC: (silica, 1:1:1:1, n-butanol, water, acetic acid, ethyl acetate)R_(f) =0.57.

NMR (D₂ O): δ 0.85 (t, 3H); 1.3-1.45 (2d, 3H); 1.55-1.7 (m, 2H);1.75-1.8 (m, 1H); 2.05-2.2 (m, 1H); 2.6-2.75 (m, 1H); 3.3-3.4 (m, 1H).

El. analysis: Calc. for C₁₇ H₁₆ NO₄ P. 1/2H₂ O N, 5.71; C, 34.29; H,6.58 Found: N, 5.74; C, 34.36; H, 6.51

Mass spectrum: FAB (m+H)=210

EXAMPLE 22 1-D-Aminoethyl-(2-carboxy-1-n-butyl)phosphinic acid ##STR38##

By the methods previously described in Example 2, but using1-(D)-benzyloxyaminoethylphosphonous acid methylester andmethyl-2-ethylsulfate, was mademethyl-1-benzyloxycarbonyl-D-aminoethyl-[2-carbomethoxy-1-n-butyl]phosphinate.

TLC: (silica, 9:1, ethylacetate:acetonitrile) R_(f) =0.58.

NMR(CDCl₃): δ 0.7-1.1 (m, 3H); 1.1-2.4 (m, 7H); 3.7 (s, 3H); 3.6-3.8 (d,3H); 3.9-4.3 (m, 1H); 5.1 (s, 2H); 5.9 (d, 1/2 H); 6.4 (d, 1/2 H); 7.2(brs, 5H).

El. analysis: Calc. for C₁₇ H₂₆ NO₆ P. 1/2H₂ O N, 3.68; C, 53.68; H,6.89 Found: N, 3.81; C, 53.63; H, 6.51

Mass Spectrum: FAB (m+H)=372 ##EQU3##

The compound was deprotected by procedures used in Example 2 to provide1-D-aminoethyl-(2-carboxy-1-n-butyl)phosphinic acid.

TLC: (silica, 1:1:1:1, n-butanol, water, acetic acid, ethyl acetate)R_(f) =0.46.

XL 300 NMR (D₂ O): δ 0.85 (overlapping t, 3H); 1.3-1.4 (overlapping d,3H); 2.55-2.7 (m, 2H); 2.75-2.9 (m, 1H); 2.05-2.2 (m, 1H); 2.6-2.85 (m,1H); 3.3-3.4 (m, 1H).

El. analysis: Calc. for C₇ H₁₆ NO₄ P. 11/4H₂ O N, 6.04; C, 36.29; H,6.96 Found: N, 6.07; C, 36.40; H, 7.27

Mass Spectrum: FAB (m+H)=210 (2m+H)=419

EXAMPLE 23 1-L-Aminoethyl-[2-carboxy-1-nonyl]-phosphinic acid ##STR39##

The title compound was made from methyl 2-n-heptylpropenoate followingthe general procedure of Example 19. Spectral data of the obtainedcompound:

    ______________________________________                                        NMR (300 MHz, D.sub.2 O): δ                                             3.2 (m, 1H)            1.6 (br s, 2H)                                         2.7 (m, 1H)            1.4 (q, 3H)                                            2.0 (m, 1H)            1.2 (br s, 10H)                                        1.7 (m, 1H)            0.8 (t, 3H)                                            Mass Spec (neg. ion FAB):                                                     278 (M-H, 100%)                                                               Elemental analysis:                                                           calc. for C.sub.12 H.sub.26 NO.sub.4 P                                                              found                                                    C: 51.60             51.53                                                   H: 9.38                9.07                                                   N: 5.01                4.78                                                   ______________________________________                                    

EXAMPLE 24 1-D-Aminoethyl-[2-carboxy-1-nonyl]-phosphinic acid ##STR40##

The compound was made from methyl 2-n-heptylpropenoate following thegeneral procedure of Example 20.

    ______________________________________                                        NMR (300 MHz, D.sub.2 O):                                                     3.2 (m, 1H)            1.6 (br s, 2H)                                         2.7 (m, 1H)            1.4 (q, 3H)                                            2.0 (m, 1H)            1.2 (br s, 10H)                                        1.7 (m, 1H)            0.8 (t, 3H)                                            Mass Spec (neg. ion FAB):                                                     278 (M-H, 100%)                                                               Elemental analysis:                                                           calc. for C.sub.12 H.sub.26 NO.sub.4 P                                                              found                                                    C: 51.60             50.97                                                   H: 9.38                9.04                                                   N: 5.01                5.02                                                   ______________________________________                                    

EXAMPLE 25 A.[1-(Benzoxycarbonylamino)ethyl](2-methoxycarbonyl-2-propenyl)-phosphinicacid ##STR41##

To a stirred solution of 2.25 g (9.3 mmol) of1-(benzyloxycarbonylamino)ethylphosphonous acid in 70 ml of methylenechloride, were added triethylamine (2.87 ml, 20 mmol), trimethylsilylchloride (2.60 ml, 20 mmol), and methyl 2-bromomethylacrylate (1.66 g,9.3 mmol) at 0° C. After stirring at room temperature for 20 hours, thereaction mixture was washed with H₂ O, 2N HCl, and then saturated NaClsolution and dried over anhydrous magnesium sulfate. The mixtureobtained by filtration and evaporation was purified by silica gelchromatography (eluted with chloroform followed by 10%methanol-chloroform) to give 2.50 g (yield 79%) of the product.

NMR (CDCl₃, δ) 1.4 (m, 3H), 2.9 (m, 2H), 3.75 (s, 3H), 4.2 (m, 1H), 5.10(s, 2H), 5.60 (d, 1H), 5.85 (m, 1H), 6.30 (m, 1H), 7.30 (s, 5H).##STR42##

B. (1-Aminoethyl)(2-carboxy-2-propenyl)phosphinic acid)

To a solution of 341 mg (1 mmol) of[1-(benzyloxycarbonylamino)-ethyl](2-methoxycarbonyl-2-propenyl)phosphinicacid in methanol (20 ml) and H₂ O (8 ml), was 1N NaOH (2.2 ml, 2.2.mmol) and the mixture was refluxed for 3 hours. After evaporation ofmethanol, the aqueous layer was washed with chloroform twice and thenacidified with 2N HCl. The aqueous solution was extracted withchloroform four times and the combined organic layer was dried overanhydrous magnesium sulfate. Filtration followed by evaporation gave 330mg (yield 100%) of[1-(benzyloxycarbonylamino)ethyl](2-carboxy-2-propenyl)phosphinic acid.The obtained above phosphinic acid (163 mg, 0.5 mmol) and sodium iodide(300 mg, 2 mmol) were dissolved in acetonitrile (3 ml). Thentrimethylsilyl chloride (0.25 ml) was added and the mixture was stirredat room temperature for 6 hours. H₂ O was added and the mixture waswashed with chloroform eight times and adjusted at pH 4 by the additionof saturated sodium carbonate solution. After evaporation to dryness,ethyl acetate (10 ml) was added and the precipitate was filtered. It wasdissolved in methanol (10 ml) and the insoluble material was filteredoff. Methanol was evaporated and the residue was purified byreversed-phase column chromatography (C-18, eluted with H₂ O) to give 60mg (yield 62%) of (1-aminoethyl)(2-carboxy-2-propenyl)phosphinic acid.

TLC (silica, butanol:acetic acid:H₂ O=4:1:2) Rf=0.15.

NMR (CD₃ OD, ) 1.4 (m, 3H), 2.8 (m, 2H), 5.4 (m, 1H), 5.9 (m, 1H)

EXAMPLE 26 (1-Aminoethyl)(2-carboxy-3-bromopropyl)phosphinic acid##STR43##

A mixture of[1-(benzyloxycarbonylamino)ethyl](2-carboxy-2-propenyl)phosphinic acid(330 mg, 1 mmol) in 30% hydrogen bromide containing acetic acid solutionwas stirred at room temperature for 4.5 hours. After ether (20 ml) wasadded, the precipitate was filtered and washed thoroughly with ether,and then it was dissolved in 2 ml of methanol. The colorless powder,which was obtained by the addition of 20 ml of propylene oxide, wasfiltered and washed with ether to afford 145 mg (yield 53%) of(1-aminoethyl)(2-carboxy-3-bromo-propyl)phosphinic acid.

TLC (silica, butanol:acetic acid:H₂ O=4:1:2) Rf=0.20

NMR (CD₃ OD,300 MH₂) 1.4 (m, 3H), 2.1 (m, 2H), 3.3 (m, 1H), 3.7 (m, 1H).

EXAMPLE 27Methyl-(1-carbobenzyloxyaminoethyl)-(2-carbomethoxy-2-propenyl)-phosphinate##STR44##

A solution of 1.053 g (4.097 mmol) phosphinate ester (synthesizedaccording to the procedure given in Example 1) in 2.5 mL distilledmethanol at 0° was treated dropwise over 10 minutes with 2.25 mL of 2.0Nmethanolic sodium methoxide (4.50 mmol; 1.1 eq.). When the addition ofbase was complete, the mixtures was stirred an additional 5 minutes at0° before a solution of 0.96 ml (1.20 g, 6.2 mmol, 1.5 eg.)trimethyl-2-phosphonoacrylate (Fluka) in 1 ml distilled methanol wasadded dropwise over 5 minutes. After 1 hour at 0°, 0.90 ml of 37%aqueous formaldehyde (Formalin) was added dropwise over 5 minutes (0.90ml=0.36 g=12 mmol=3 eq.). The mixture was warmed to room temperature andstirred at room temperature for 2 hours.

The reaction was quenched at 0° by addition of 20 mL ethyl acetate and 5mL 1N HCl. The organic layer was removed and the aqueous layerre-extracted with 5 mL ethyl acetate. The combined organic extracts werewashed with 2×5 mL brine then filtered through a plug of anhydroussodium sulfate onto anhydrous magnesium sulfate. The solution wasfiltered and all volatiles removed under vacuum to afford a pale yellowoil which was purified by medium pressure liquid chromatography onsilica, eluting with 9/1 ethyl acetate/acetonitrile. Purification inthis manner afforded 1.181 g (3.33 mmol; 81%) of the title compound as aviscous oil.

    ______________________________________                                        NMR (300 MHz, CDCl.sub.3): δ                                            7.3-7.4    (m, 5H)       4.2    (m, 1H)                                       6.4        (d, 1H)       3.75   (m, 6H)                                       5.8        (d, 1H)       3.0    (q, 2H)                                       5.2        (s, 2H)       1.4    (q, 3H)                                       5.1        (br s, 1H)                                                         Mass Spec (EI):                                                               M.sup.+ 355 (.5%)                                                             Elemental Analysis:                                                           calc. for C.sub.16 H.sub.22 NO.sub.6 P                                                             found                                                     C: 54.08            53.01                                                    H: 6.24               6.19                                                    N: 3.94               3.73                                                    ______________________________________                                    

TLC: (ethylacetate/n-butanol/acetic acid/water; 1:1:1): R_(f=) 0.85.

EXAMPLE 28 1-Aminoethyl-(2-carboxy-3-chloro-n-proypl) Phosphinic Acid##STR45##

Methyl(1-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-2-propenyl)phosphinatefrom Example 27 (101 mg, 0.296 mmol) was suspended in 4 ml concentratedhydrochloric acid and heated at 50° for two weeks.

Reaction mixture diluted to 15 mL with distilled water and washed 3×5 mLwith ethyl acetate. The aqueous layer was evaporated to dryness, theresidue dissolved in 5 mL distilled water and freeze-dried to afford apale yellow solid. The solid was dissolved in 1 mL absolute methanol andtreated with excess propylene oxide. The precipitate was filtered offand dried under vacuum to afford 52 mg (0.23 mmol; 75%) of the titlecompound as a white powder.

    ______________________________________                                        NMR (200 MHz, D.sub.2 O) δ                                              3.9 (m, 2H)            2.0 (m, 1H)                                            3.3 (m, 2H)            1.5 (q, 3H)                                            2.2 (m, 1H)                                                                   Mass Spec (NI-FAB)                                                            M-H 228 (100%)                                                                ______________________________________                                    

EXAMPLE 29 1-Aminoethyl-(2-carboxy-5-phenyloct-2-enyl) phosphinic acid(E and Z isomers) ##STR46## A.Methyl-1-benzyloxycarbonylaminoethyl-(2-carbomethoxy-5-phenyloct-2-enyl)phosphinate(E & Z isomers)

The title compounds were obtained from1-benzyloxycarbonylaminoethylphosphonous acid methyl ester (1.054 gm,4.1 mmol), 2-trimethylphosphonoacrylate (1.2 gm, 6.18 mmol), andphenylpropionaldehyde (1.63 gm, 12.2 mmol) by a method described inExample 27. Chromatographic separation (silica, 9:1,ethylacetate:acetonitrile) afforded the Z isomer of the title compound(0.929 gm) and the E isomer of the title compound (0.654 gm) as oils.

TLC (silica, 9:1:0.5, ethylacetate:acetonitrile:methanol) R_(f) =0.67(both isomers).

    ______________________________________                                        NMR (300 MHz, CDCl.sub.3):                                                    Z isomer                 E isomer                                             ______________________________________                                        7.2-7.4    (m, 10H)      7.2-7.4 (m, 10H)                                     7.0        (m, 1H)       6.2     (m, 1H)                                      5.5        (d, .5H)      5.4     (d, .5H)                                     5.1        (m, 2.5H)     5.1     (m, 2.5H)                                    4.1        (m, 1H)       4.1     (m, 1H)                                      3.7        (m, 6H)       3.7     (m, 6H)                                      2.6-3.0    (m, 6H)       2.7-3.0 (m, 6H)                                      1.3        (m, 3H)       1.3     (m, 3H)                                      Mass Spec (EI):                                                               E isomer:  459 (M+, 1%)                                                       Z isomer:  459 (M+, 1%)                                                       ______________________________________                                    

B. 1-Aminoethyl-(2-carboxy-5-phenyloct-2-enyl)phosphinic acid (E & Zisomers)

Treatment of each of the E and Z isomers ofmethyl-1-benzyloxycarbonylaminoethyl(2-carbomethoxy-5-phenyloct-2-enyl)phosphinatewith concentrated hydrochloric acid as described in Example 33 affordedthe hydrochloride salts (66% yield for E isomer, 79% for Z isomer) ofthe title compounds as white powders. TLC (silica, 1:1:1:1.ethylacetate:n-butanol:acetic acid:water) R_(f) Z-isomer=0.59E-isomer=0.57.

    ______________________________________                                        NMR (200 MHz D.sub.2 O):                                                      Z isomer                  E isomer                                            ______________________________________                                        7.2-7.4   (m, 5H)         7.2-7.4 (m, 5H)                                     6.8       (m, 1H)         6.0     (m, 1H)                                     3.3       (m, 7H)         3.1-3.3 (m, 7H)                                     1.3       (q, 3H)         1.3     (q, 3H)                                     Mass Spec (NI FAB):                                                           E isomer: 296 (M-H, 100%)                                                     Z isomer: 296 (M-H, 100%)                                                     ______________________________________                                    

EXAMPLE 30 1-Aminoethyl-(2-carboxy-oct-2-enyl)phosphinic acid (E/Zmixture) ##STR47## A. Methyl1-t-butoxycarbonylaminoethyl-(2-carbomethoxy-oct-2-enyl)phosphinate (E/Zmixture)

The title compound was prepared form1-t-butoxycarbonylaminoethylphosphonous acid methyl ester (0.616 gm,2.76 mmol), (example 36) 2-trimethylphosphonoacrylate (1.07 gm, 5.54mmol), and hexanal (0.55 gm, 5.5 mmol) by the method described inExample 27. the product was purified by chromatography (silica, 5%methanol in ethylacetate) to give the title compound (0.805 gm) as amixture of E/Z isomers.

TLC (silica, 9:1:0.5, ethylacetate:acetonitrile:methanol) R_(f) =0.40

    ______________________________________                                        NMR (300 MHz, CDCl.sub.3):                                                    7.0      (m, 5H, Z isomer)  2.5   (m, 1H)                                     6.2      (m, 5H, E isomer)  2.3   (m, 1H)                                     5.0      (m, 1H)            1.9   (m, 1H)                                     4.1      (m, 1H)            1.5   (s, 9H)                                     3.7      (m, 6H)            1.3   (m, 8H)                                     3.0      (m, 2H)            0.9   (t, 3H)                                     Mass Spec (FAB)                                                               392 (M + H, 38%)                                                              Elemental Analysis:                                                           calc. for C.sub.18 H.sub.34 NO.sub.6 P.1/2H.sub.2 O                                               found                                                      C: 53.99           53.23                                                     H: 8.80              8.30                                                     N: 3.50              3.51                                                     ______________________________________                                    

B. 1Aminoethyl-(2-carboxy-1-oct-2-enyl)phosphinic acid (E/Z isomermixture)

The title compound was prepared fromMethyl-1-t-butoxycarbonylaminoethyl-(2-carbomethoxy-1-oct-2-enyl)phosphinate(0.176 gm, 0.45 mmol) by stirring in concentrated HCl according toExample 33. The title compound as its hydrochloride salt (0.105 gm) wasobtained as a hygroscopic white powder.

TLC (silica, 1:1:1:1, ethylacetate:n-butanol:acetic:water) R_(f) =0.57

    ______________________________________                                        NMR (300 MHz, CD.sub.3 OD):                                                   7.0     (m, 5H, Z isomer)                                                                              2.4     (m, 1H)                                      6.2     (m, 5H, E isomer)                                                                              2.2     (m, 2H)                                      3.3     (m, 1H)          1.2-1.5 (m, 8H)                                      2.8     (m, 2H)          0.8     (br s, 3H)                                   Mass Spec (NI FAB):                                                           262 (M-H, 100%)                                                               ______________________________________                                    

EXAMPLE 31 ##STR48##Methyl(1-D-Benzyloxycarbonylamino)ethyl)-(2-carbomethoxy-2-propenyl)phosphinate

A solution of 1.0405 g (4.05 mmol)1-(D)-benzyloxycarbinylaminoethylphosphonous acid methyl ester in 2.5 mLdistilled methanol at 0° was treated dropwise over 10 minutes with 2.2mL of 2.0N methanolic sodium methoxide (4.4 mmol; 1.1 eq.). When theaddition of base was complete, the mixture was stirred an additional 5minutes at 0° before a solution of 0.94 ml (1.18 g, 6.1 mmol, 1.5 eq.)trimethyl-2-phosphonoacrylate (Fluka) in 1 ml distilled methanol wasadded dropwise over 5 minutes. After 1 hour at 0°, 0.93 ml of 37%aqueous formaldehyde (Formalin) was added dropwise over 5 minutes (0.93ml=0.37 g=12 mmol=3 eq.). The mixture was warmed to room temperature andstirred at room temperature for 3 hours.

The reaction was quenched at 0° by addition of 20 mL ethylacetate and 5mL 1N HCl. The organic layer was removed and the aqueous layerre-extracted with 5 mL ethylacetate. the combined organic extracts werewashed with 2×5 mL brine then filtered through a plug of anhydroussodium sulfate onto anhydrous magnesium sulfate. The solution wasfiltered and all volatiles removed under vacuum to afford a pale yellowoil which was purified by medium pressure liquid chromatography onsilica, eluting with 5% methanol/ethylacetate. Purification in thismanner afforded 1.091 g (3.07 mmol; 75%) of pure title compound as aviscous oil.

    ______________________________________                                        NMR (300 MHz, CD.sub.3 OD):                                                   7.3-7.4    (m, 5H,)      4.2    (m, 1H)                                       6.4        (d, 1H)       3.75   (m, 6H)                                       5.8        (d, 1H)       3.0    (dd, 2H)                                      5.2        (s, 2H)       1.4    (dd, 3H)                                      5.1        (brs, 1H)                                                          Mass Spec (EI): 355 (.5%), M.sup.+                                            Elemental Analysis:                                                           calc. for C.sub.16 H.sub.22 NO.sub.6 P.1/2 H.sub.2 O                                              found                                                      C: 52.75           53.01                                                     H: 6.36             6.19                                                      N: 3.85             3.73                                                      R.sub.f (ethylacetate/n-butanol/acetic acid/water: 1:1:1:1):                  ______________________________________                                        .85                                                                       

EXAMPLE 32 ##STR49##(1-D-Benzyloxycarbonylamino)ethyl)-(2-carbomethoxy-2-propenyl)phosphinicacid

Under nitrogen, a solution ofMethyl(1-D-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-2-propenyl)phosphinate(2.26 g, 6.34 mmol) in 10 mL dry THF at room temperature was treatedwith 0.94 g (7.0 mmol, 1.1 eq.) anhydrous lithium iodide. The mixturewas stirred at room temperature for 72 hours at which time tlc(ethylacetate/n-butanol/acetic acid/water; 1:1:1:1) indicated completeabsence of starting material with appearance of the product with Rf of0.70.

All volatiles were removed under vacuum and the residue redissolved in30 mL 5% aqueous sodium bicarbonate and washed with ethylacetate (5×10mL). The aqueous layer was cooled to 0° and made acidic (pH 1) by theslow addition of 6N HCl. The acidified mixture was extracted withethylacetate (6×10 mL); the combined organic extracts washed once withbrine and filtered through a plug of anhydrous sodium sulfate ontoanhydrous magnesium sulfate. Filtration and removal of solvent in vacuoafforded the title compound (1.779 g, 5.22 mmol, 82%) as a pale yellowsolid.

    ______________________________________                                        NMR (300 MHz, CD.sub.3 OD): δ                                           7.3-7.4     (m, 6H,)      4.0   (m, 1H)                                       6.3         (d, 1H,)      3.7   (m, 3H)                                       5.8         (d, 1H)       3.0   (d, 2H)                                       5.1         (br s, 2H)    1.3   (dd, 3H)                                      Mass Spec (FAB): 342 (100%), M + H                                            Elemental Analysis:                                                           calc. for C.sub.15 H.sub.20 NO.sub.6 P.1/2H.sub.2 O                                               found                                                      C: 51.43           51.09                                                     H: 6.03             5.67                                                      N: 4.00             4.02                                                      R.sub.f (ethylacetate/n-butanol/acetic acid/water: 1:1:1:1):                  ______________________________________                                        0.70                                                                      

EXAMPLE 33 ##STR50##(1-D-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-2-D-methyl-1-ethyl)phosphinicAcid

A solution of 0.172 g (0.504 mmol) of1-D-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-2-propenyl)phosphinicacid in 3 mL of dry methanol and 0.5 mL of benzene was hydrogenated at40 psi in the presence of 25 mg of 1,5 cyclooctadiene-rhodium (I)chloride dimer and 70 mg of(-)2,3-O-isopropylidene-2,3-dihydroxy-1,4-(diphenylphosphino)butane ((-)DIOP)). Hydrogen uptake was complete after 3 hours. the mixture wasdiluted with 10 mL of ether, cooled to 0° C. and filtered to removeproduct. The crude product was recyrstallized 3 times from aqueousacetic acid to give the title compound.

    ______________________________________                                        NMR (300 MHz, CD.sub.3 OD): δ                                           7.3-7.5     (m, 6H)       2.2   (m, 1H)                                       5.1         (dd, 1H)      1.8   (m, 1H)                                       4.0         (m, 1H)       1.3   (dd, 3H)                                      3.7         (s, 3H)       1.2   (d, 3H)                                       2.9         (m, 1H)                                                           Mass Spec (NIFAB): 342 (40%), M-H                                             Elemental Analysis:                                                           calc. for C.sub.15 H.sub.20 NO.sub.6 P                                                              found                                                    C: 52.48             52.49                                                   H: 6.46               6.16                                                    N: 4.08               4.25                                                    R.sub.f (ethylacetate/n-butanol/acetic acid/water: 1:1:1:1): 0.70             Optical Rotation: +30.1° (CH.sub.3 OH, c = .3)                         ______________________________________                                    

EXAMPLE 34 ##STR51##(1-D-Aminoethyl)-(2-carboxy-2-D-methyl-1-ethyl)phosphinic acid

(1-D-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-2-D-methyl-1-ethyl)phosphinicacid was converted to the title compound in 60% yield by proceduresdescribed in Example 2.

    ______________________________________                                        NMR (300 MHz, D.sub.2 O): δ                                             3.25       (m, 1H,)      1.68   (m, 1H)                                       2.81       (d, 1H,)      1.38   (dd, 3H)                                      2.10       (d, 1H)       1.27   (d, 3H)                                       Mass Spec (NIFAB): 194 (55%), M-H                                             R.sub.f (ethylacetate/n-butanol/acetic acid/water: 1:1:1:1):                  ______________________________________                                        0.35                                                                      

EXAMPLE 35 1-Aminoethyl-(2-carboxy-(4-phenyl-2-Z-butenyl))phosphinicacid ##STR52## A.Methyl(1-Benzyloxycarbonylaminoethyl)-(2-carbomethoxy-(4-phenyl-2-Z-butenyl))phosphinate

The title compound was prepared from1-benzyloxycarbonylaminoethylphosphonous acid methyl ester (1.154 gm,4.49 mmol), 2-trimethylphosphonoacrylate (1.31 g,, 6.7 mmol), andphenylacetaldehyde (1.08 gm, 8.9 mmol) by the procedure described inexample 29. The crude product was purified by chromatography (silica,9:1, ethylacetate:acetonitrile) to give 0.41 gm of the title compound.

TLC (silica, 9:1:0.5, ethylacetate:acetonitrile:methanol) R_(f) =0.70.

    ______________________________________                                        NMR (300 MHz, CD.sub.3 Cl.sub.3): δ                                     7.0-7.4     (m, 11H,)      3.7   (m, 6H)                                      5.5         (d, .5H)       3.6   (m, 2H)                                      5.1         (m, 2.5H)      3.1   (m, 2H)                                      4.1         (m, 1H)        1.4   (q, 3H)                                      Mass Spec (FAB):                                                              446 (M + H, 100%)                                                             Elemental Analysis                                                            calc. for C.sub.23 H.sub.28 NO.sub.6 P.1/2H.sub.2 O                                               found                                                      C: 60.79           60.03                                                     H: 6.43             6.11                                                      N: 3.08             3.14                                                      ______________________________________                                    

B. 1-Aminoethyl-(2-carboxy-(4-phenyl-2-Z-butenyl))phosphinic acid

1-Benzyloxycarbonylaminoethyl-(2-carbomethoxy-(4-phenyl-2-Z-butenyl)phosphinicacid methyl ester (0.1 gm, 0.23 mmol) was stirred for 1 week inconcentrated HCl (5 mL). After concentration in vacuo, the hydrochloridesalt of the title compound (0.051 gm) was obtained as a white powder.TLC (silica, 1:1:1:1, ethylacetate:n-butanol:acetic acid:water) R_(f)=0.43.

    ______________________________________                                        NMR (200 MHz, D.sub.2 O): δ                                             7.0-7.8    (m, 6H,)        3.0   (m, 2H)                                      3.7        (m, 2H)         1.5   (q, 3H)                                      3.4        (m, 1H)                                                            Mass Spec (NI FAB):                                                           282 (M-H, 55%)                                                                ______________________________________                                    

EXAMPLE 36 1-t-Butoxycarbonylaminoethylphosphonous acid methylester

The title compound was prepared in 63% yield according to the proceduresdescribed in Example 1 with the only variant being thatdi-t-butyldicarbonate was used to protect the amino group in place ofbenzylchloroformate. The title compound was purified by chromatography(silica, 9:1,ethylacetate:acetonitrile).

TLC (silica, 10:1,ethylacetate:ethanol) R_(f) =0.70.

NMR (300 MHz, CDCl₃) 1.3 (m, 3H); 1.4 (s, 9H); 3.8 (d, 3H); 4.0 (m, 1H);4.8 (br d, 1H); 6.1 (s, 0.5H) 7.9 (s, 0.5 H).

What is claimed is:
 1. A pharmaceutical composition useful in thetreatment of antibacterial infections which comprises a pharmaceuticallyacceptable carrier and a pharmaceutically effective amount to treatbacterial infections of an antibacterial compound of formula I:##STR53## wherein R₁ isH, or CH₃ ; R₂ is(a) hydrogen; (b) C₁ -C₁₂ linearor branched alkyl; (c) C₁ -C₁₂ linear or branched monoalkenyl; (d) C₇-C₂₀ aralkyl, wherein the alkyl chain is linear or branched C₁ -C₈ andwherein said above values from R₂ can be substituted by one halo,hydroxy, carboxy, C₁ -C₄ alkoxycarbonyl, C₇ -C₁₆ arylalkoxycarbonyl, C₃-C₇ cycloalkyl, C₁ -C₄ alkoxy, C₆ -C₁₂ aryloxy, amino, mono- or di-C₁-C₈ alkylamino, thio, C₁ -C₄ alkylthio, C₆ -C₁₂ arylthio, C₇ -C₁₆aralkylthio, or the radical --S--(CH₂)_(n) --CH--(NH₂)COOH, where n=1-2;with the proviso that R₂ is at least C₂ alkyl if substituted by one ofthe above-defined thio groups, and wherein the aryl ring can be furthersubstituted by one C₁ -C₄ linear or branched alkyl, trihalomethyl,nitro, halo, cyano or sulfonamido; R₃ and R₄ arehydrogen, C₁ -C₄alkyl;wherein the carbon atoms attached to R₁ are D(S) or DL(SR) and R₂are D(R) or DL(RS) stereoconfiguration.
 2. The composition of claim 1wherein the compound contains the carbon atoms attached to R₁ and R₂ inthe D(S), D(R) configurations, respectively.
 3. The composition of claim1 in which the compound is 1-(aminoethyl)-(2-carboxy-n-propyl)phosphinic acid.
 4. The composition of claim 1 in which the compound is1-(aminoethyl)-(2-carbomethoxy-n-propyl) phosphinic acid.
 5. Thecomposition of claim 1 in which the compound is1-(aminoethyl)-(2-carboxy-n-butyl) phosphinic acid.
 6. The compositionof claim 1 in which the compound is 1-(aminoethyl)-(2-carboxy-n-nonyl)phosphinic acid.
 7. The composition of claim 1 in which the compound is1-(aminoethyl)-(2-carboxy-3-chloro-n-propyl) phosphinic acid.
 8. Thecomposition of claim 1 in which the compound is1-(aminoethyl)-(2-carboxy-3-bromo-n-propyl) phosphinic acid.
 9. Thecomposition of claim 1 in which the compound is1-(aminoethyl)-(2-carboxy-n-hexyl) phosphinic acid.
 10. A method fortreating a bacterial infection in a mammalian host comprisingadministering to said host a therapeutically effective amount to treatbacterial infections of the composition of claim 1.